Investing analyses

# ALAB — Earnings Review Q4 FY25 (Atlas)

> Date: 2026-02-23 (updated from 2026-02-21 with stage outputs: quant-prep, transcript-digest, scuttlebutt)
> Quarter: Q4 FY25 (Dec-2025)
> Market cap: $28.7B | EV/TTM Rev: ~32x | Revenue growth: 92% YoY

## Verdict

Astera Labs delivered a clean Q4 beat — $270.6M revenue (+92% YoY, +17.5% QoQ) against $250.5M guide, the 4th consecutive beat averaging 9%. The core business is executing. But three things dominated the post-earnings reaction and justify the ~20% stock drop: gross margin guided to 74% for Q1 (structural, not cyclical), GAAP net income collapsed from $91.1M in Q3 to $45.0M in Q4 despite $40M revenue growth, and the CFO is departing mid-hyper-growth. Scorpio+Taurus jumped from ~15% to ~30% of revenue in a single quarter — a product inflection that expands TAM but compresses margins. The Amazon $6.5B warrant provides long-term demand visibility at an unknown price point. At ~32x TTM revenue decelerating toward 37% annualized (per Q1 guide), valuation leaves no margin for error. **Conviction: 3** — hold. Not adding until gross margin trajectory stabilises and Scorpio X ramp demonstrates growth reacceleration.

## Qualification Gate

| Criterion | Threshold | Actual | Pass? |
|-----------|-----------|--------|-------|
| Revenue YoY growth | >30% | 92% | PASS |
| Gross margin | >60% | 75.6% [GAAP] | PASS |
| Revenue per quarter | >$50M | $270.6M | PASS |
| Data availability | 4+ quarters | 12 quarters | PASS |
| Share dilution | <10% annual | ~6% (169M→181M FY25) | PASS |
| GAAP profitability | Improving or positive | GAAP NI $45M Q4; $219M FY25 | PASS |

All six gates pass. SBC at 15.3% of revenue (declining from 18.8% a year ago) is appropriate for a post-IPO semiconductor company in hyper-growth.

## Six-Factor Score

| Factor | Rating | Detail |
|--------|--------|--------|
| Growth | Strong | 92% YoY Q4; 115% FY25. Deceleration from 144%→150%→104%→92% is mechanical base normalisation. Sequential dollar adds: $18

*…truncated*

# ALAB — Astera Labs Q4 FY25 Earnings Review
**Date:** 2026-02-22 | **Period:** Q4 FY25 (quarter ending Dec 31, 2025)
**Position:** Long ALAB, 5.2%

---

## Verdict

Solid beat, but the trajectory is decelerating and the market is right to reprice. Stock -20% post-earnings is the market smelling what the data shows: three consecutive quarters of YoY deceleration, gross margin guided lower, and a CFO departure at an awkward moment. I'm holding but not adding. Scorpio X is the re-acceleration catalyst — if H2 FY26 doesn't deliver it, I trim.

---

## Revenue Grid

|  | Q1 FY24 (Mar-24) | Q2 FY24 (Jun-24) | Q3 FY24 (Sep-24) | Q4 FY24 (Dec-24) | Q1 FY25 (Mar-25) | Q2 FY25 (Jun-25) | Q3 FY25 (Sep-25) | Q4 FY25 (Dec-25) | Q1 FY26E (Mar-26E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue ($m) | ~53 | ~68 | ~116 | ~141 | ~133 | ~171 | ~278 | 270.6 | 286–297 |
| YoY % | 179% | 144% | 150% | 104% | ~151% | ~151% | ~140% | 92% | ~62%E |
| QoQ % | — | ~28% | ~71% | ~21% | ~-6% | ~29% | ~63% | -3% | ~8%E |

> Note: Q1-Q3 FY25 individual quarters estimated from FY25 total ($852.5m) and known Q4 ($270.6m). Q4 FY24 = $270.6m / 1.92 ≈ $141m.

**Beat history:**
| Quarter | Guide | Actual | Beat |
|---------|-------|--------|------|
| Q2 FY25 | $155m | ~$171m | +10.3% |
| Q3 FY25 | $207m | ~$278m | +11.5% |
| Q4 FY25 | $251m | $270.6m | +8.0% |

Consistent beat pattern, but magnitude narrowing slightly. Management guides conservatively — factor this in when sizing Q1 FY26.

---

## Trajectory Assessment

**YoY: DECELERATING.** 150% → 104% → 92% is three straight quarters down. Absolute growth rates are impressive at scale — 92% YoY on $271m is not trivial — but my framework calls two quarters of deceleration as the sell signal. We're at three.

**The mitigating case:** Q1 FY26 guide of ~$291.5m midpoint implies ~62% YoY growth, which continues the deceleration trend. The Scorpio X ramp is supposed to inflect this in H2 FY26. That's the entire re-acceleration thesis. Without it,

*…truncated*

# ALAB — Earnings Review Q4 FY25 (Phil Fisher)

> Date: 2026-02-22
> Quarter: Q4 FY25 (December 2025)
> Framework: Fisher Fifteen Points, Scuttlebutt, Growth Arc
> Atlas baseline: Conviction 3 (Hold, not add)

---

## Opening Assessment

I have spent a considerable portion of my career observing companies that are, as I have written, "fortunate because they are able." The distinction matters enormously. A great many companies ride secular tailwinds to prosperity — the oil companies of the postwar era, the defense contractors of the Cold War — and would have prospered under almost any competent management. The genuinely outstanding companies are those where management itself creates the opportunity, where engineering talent and organizational clarity open doors that competitors cannot find.

Astera Labs is, in my view, in that second and rarer category.

The company delivered Q4 FY25 revenue of $270.6 million, representing 92% year-over-year growth, against guidance of $250.5 million. The full year FY25 reached $852.5 million, 115% above FY24. These numbers alone would satisfy most investors. But the Fisher method requires us to look behind the numbers, to understand the people who produced them, the competitive position that made them possible, and the runway that lies ahead. That is what I shall attempt here.

---

## The Fifteen Points — Assessment

### Point 1: Does the company have products or services with sufficient market potential to make possible a sizeable increase in sales for at least several years?

**PASS — Emphatically.**

The connectivity layer between AI accelerators, fabric switches, and memory is not a niche. It is the plumbing through which all AI computation flows. Astera's management has estimated their served addressable market will expand tenfold to $25 billion over five years, with the merchant scale-up switching opportunity alone reaching $20 billion annually by 2030.

I am not in the habit of accepting management's TAM projections uncritic

*…truncated*

# ALAB — Astera Labs Q4 FY25 Earnings Review

> **GauchoRico | February 25, 2026**
> **Quarter Ending:** December 31, 2025
> **Task Type:** Earnings Review
> **Prior Position:** 12.5% (shares only)

---

## The Headline Debate: Is the Amazon Deal a Game-Changer or a Margin Trap?

The Feb 10 8-K filed the same night as earnings told you everything. Amazon issued Astera 3.3M warrant shares in exchange for a committed purchase agreement — up to $6.5B through 2033, averaging roughly $800M/year across smart fabric switches, signal conditioning, and optical solutions. That's more than Astera's entire FY25 revenue in a single annual guarantee from a single customer.

Let me be direct about what this is: it is simultaneously the most bullish demand signal I have seen from a semiconductor company this size, and the structural cause of every margin problem we are going to be talking about for the next six quarters.

The bull reading is obvious. $6.5B over seven years is not a capex commitment you extract from Amazon unless they have architecturally embedded your products in something they intend to build at massive scale. Amazon does not sign $6.5B deals for fun. This is Scorpio and Taurus going into AWS AI infrastructure at volume. If ALAB executes on this demand, we are looking at a company doing $1.5B+ in revenue by FY27 with a genuinely defensible position inside the largest hyperscaler on earth.

The bear reading is also obvious. Those warrants create roughly 200 basis points of quarterly gross margin drag starting Q2 FY26. Management confirmed it. Combined with the natural mix shift toward Scorpio/Taurus (lower margins than Aries), you are staring at a gross margin that goes from 77% at the peak in Q1 FY25 to potentially 70-72% by the time the mix fully rebalances. That is a 500-700bp structural compression over 18 months. For a stock at 33x TTM revenue, that is not a rounding error.

My read: the Amazon deal is a real game-changer on demand. But the margin math is also

*…truncated*

# ALAB — Earnings Review Q4 FY25

> Bear (PaulWBryant / Drew)
> Date: 2026-02-22
> Quarter: Q4 FY25 (Dec-25)
> Market cap: ~$28.7B | TTM P/S: ~32x | TTM Revenue: $852.5m

---

## First Look

I haven't written about Astera Labs before, so let me be upfront: this is my first application of the framework to ALAB. I'll note where I'm working from first principles vs. established prior views. No position held.

The headline: a genuinely impressive business delivering a clean beat at $270.6m (+92% YoY, +17.5% QoQ), guide of $291.5m midpoint for Q1 FY26. The market disagreed — stock dropped ~20% post-earnings. When that happens, I pay attention. Either the market is wrong, or the market saw something in the details worth understanding.

In this case, I think the market was partially right.

---

## Prior Beliefs / Updated Beliefs

| Metric | Prior Belief | Actual | Assessment |
|--------|-------------|--------|------------|
| Q4 revenue vs. guide | Beat by 8-11% (consistent pattern) | $270.6m, +8.0% vs. $250.5m guide | Consistent. 4Q avg beat: +9.0% |
| Gross margin | Stable ~76% | 75.6% [GAAP] — and guided 74% Q1 | Worse than expected directionally |
| Scorpio contribution | Growing, possibly 20%+ of Q4 | Scorpio+Taurus = 30% combined | Better than expected on mix; problem is the margin implication |
| Q1 guide | ~$275-285m (extrapolating beat pattern conservatism) | $291.5m midpoint | Guided above what I'd have projected — bullish |
| Operating leverage | Should be improving | Non-GAAP op margin 40.2% — but R&D up $16m QoQ | Flat to slightly down. Investing aggressively. |
| CFO stability | Assumed continuity | Mike Tate departing, Desmond Lynch starts March 2 | Unexpected. Yellow flag. |
| Amazon relationship | Significant customer | 8-K: $6.5B cumulative warrant through 2033 | Formalized — impressive demand floor, but price? |

**Delta summary:** The beat and Q1 guide are good. The gross margin trajectory and CFO departure are not. The Amazon warrant sounds great until

*…truncated*

# ALAB — Earnings Review Q4 FY25 (Saul)

> Date: 2026-02-22
> Quarter: Q4 FY25 (Dec-25)
> Revenue: $270.6m | YoY: +92% | QoQ: +17.5%
> Non-GAAP EPS: $0.58 | Non-GAAP Op Margin: 40.2% | FCF Margin: 33.1%

---

## Verdict: Thesis Intact — Strong Quarter, Market Overreacted to Margin Noise

Let me just say this upfront: revenue of $270.6 million, up 92% year-over-year, beating guidance by $20 million — that is a preposterous result for a semiconductor company! And the market punished the stock 20%!

I want to be clear about what happened here. Astera Labs beat on revenue, beat on earnings, delivered 40% non-GAAP operating margins, generated $282 million in free cash flow for the full year, and guided to continued growth of $291 million at the midpoint for next quarter. And the market sold it off 20% because gross margins were guided to 74% instead of 76%.

I follow the money, the results. And the results here are really, really strong.

---

## Revenue Trajectory — This Is What Matters Most

| Quarter | Revenue | YoY | QoQ $ | QoQ % |
|---------|---------|-----|-------|-------|
| Q1 FY25 | $159.4m | +144% | +$18m | +13% |
| Q2 FY25 | $191.9m | +150% | +$33m | +20% |
| Q3 FY25 | $230.3m | +104% | +$38m | +20% |
| Q4 FY25 | $270.6m | +92% | +$40m | +18% |
| Q1 FY26e | $291.5m | ~+54% | +$21m | +8% |

Look at those sequential dollar adds: $18m → $33m → $38m → $40m. The absolute dollars added every quarter are growing! That is what a healthy business looks like. The YoY percentages are "decelerating" because a year ago this company was tiny — $65 million in Q1 FY24 versus $159 million in Q1 FY25. Mathematical base effects, nothing more.

The Q1 guide of $21m sequential adds is admittedly a step-down, and I'm watching that. But I've seen ALAB guide conservatively and beat by 9% on average across four consecutive quarters. The true number is probably closer to $25-30m sequential adds.

**Full year FY25: $852 million, up 115% from FY24's $396 million.** That is just an astoun

*…truncated*

# ALAB — Astera Labs: Q4 FY25 Earnings Review
*StockNovice (Joe) | February 2026*

---

## The Quarter

Strong beat. ALAB posted $270.6m revenue vs ~$250m consensus — about $20m upside. That's +92% YoY and +18.6% QoQ. For context: they guided $245-255m. Coming in at $270.6m when the high end of your guide was $255m is a real beat, not a marginal one.

FY25 totals: $852.5m, +115% YoY. Two years ago this was a $17.7m/quarter company. The growth has been extraordinary.

**The metrics:**

| Metric | Q4 FY25 | Q4 FY24 | YoY |
|--------|---------|---------|-----|
| Revenue | $270.6m | $140.8m | +92% |
| Gross Margin [Non-GAAP] | 75.7% | 77.3% | -160bps |
| Op Margin [Non-GAAP] | 40.2% | 35.3% | +490bps |
| EPS [Non-GAAP] | $0.58 | $0.36 | +61% |
| FCF (FY25) | $281.8m | — | 33.1% margin |

Product mix is shifting fast. Scorpio P crossed >15% of revenue. Ares (PCIe retimers) is still the core but Taurus (Ethernet cables) is up 4x+, and Scorpio X (fabric switches) just started shipping. The story is broadening beyond PCIe retimers.

---

## "Is" vs "Could Be"

Here's my honest read:

**What's "is":** Astera is delivering today. 92% growth at scale (nearly $1B run rate), 40% non-GAAP operating margins, $282m FCF for FY25. Scorpio P is real and growing. Amazon is a major customer with a $6.5B warrant through 2033 — that's not vaporware, that's a contractual relationship.

**What's "could be":** Scorpio X ramp, CXL memory platform (the Microsoft/Intel/SAP partnership), the $25B TAM expansion thesis. The Scorpio X just started shipping. CXL is genuinely early. These are real opportunities but they haven't shown up in the revenue line in a meaningful way yet.

I don't use "could be" to size positions. Story elements get tryout-sized at most.

---

## The Deceleration Problem

This is the thing I keep coming back to. Q4 beat hard. But Q1 FY26 guide is $286-297m — midpoint $291.5m. That's +7.7% QoQ sequential growth. Annualize that and you're looking at ~37% growth. Compare that t

*…truncated*

---
# ALAB — Astera Labs | Q4 FY25 Earnings Review
**Date:** 2026-02-22 | **Reported:** 2026-02-10 | **Quarter:** Q4 FY25 (Dec 2025)
**Long ALAB ~5.2%**

---

## Links
- Transcript: Motley Fool Q4 FY25
- PR: asteralabs.gcs-web.com
- 8-K: Amazon warrant (3.3m shares, $6.5B cumulative through 2033)
- CFO transition 8-K: Desmond Lynch (ex-Rambus) effective March 2, 2026

---

## Atlas Baseline

Atlas scored this Conviction 3 (hold, not add). Key points: strong Q4 beat (+8%), structural GM compression, Amazon pricing risk, CFO departure, CRDO dramatically cheaper on growth-adjusted basis (~0.08x EV/Rev/$growth vs. ALAB ~0.35x). Market punished ~20% post-earnings.

**My read:** Atlas is directionally right on valuation vs. CRDO. But Atlas underweights the platform optionality of what Astera is actually building. That's where muji adds nuance.

---

## Financial Summary

**Revenue trajectory:**
+269% → +619% → +207% → +179% → **+144% → +150% → +104% → +92%** (FY25)

| | Q125 | Q225 | Q325 | Q425 | Q126 (guide) |
|---|---|---|---|---|---|
| | Mar-25 | Jun-25 | Sep-25 | Dec-25 | Mar-26 |
| Revenue ($m) | 159.4 | 191.9 | 230.3 | **270.6** | 286–297 |
| YoY % | 144% | 150% | 104% | **92%** | ~37% |
| QoQ % | +13% | +20% | +20% | **+17.5%** | ~+7.7% |
| GM [Non-GAAP] | 77.2% | 76.7% | 76.3% | **75.7%** | ~74% |
| Op Margin [Non-GAAP] | 33.8% | 39.2% | 41.7% | **40.2%** | — |
| EPS [Non-GAAP] | $0.33 | $0.44 | $0.49 | **$0.58** | $0.53–0.54 |
| Beat vs. guide | +5.2% | +11.2% | +11.7% | **+8.0%** | — |

**FY25 summary:** Revenue $852.5m (+115%) | FCF $281.8m (33.1% margin) | Net cash $1,188.8m | Zero debt.

Rule of 40: 92 YoY + 40 op margin = **132 !!** (extraordinary, even if forward normalizes to ~77)

---

## Platform Assessment — This Is the Key

Here's the thing — Astera is NOT a signal conditioning company. That's where they started (Ares PCIe retimers). What they're building is a full AI connectivity platform. Let me map the product stack:

**Layer 1 — Signal Conditionin

*…truncated*

# ALAB — Astera Labs Q4 FY25 Earnings Review

> Date: 2026-02-25
> Quarter: Q4 FY25 (ended Dec-2025)
> Market cap: ~$28.7B | EV/TTM Rev: ~33x | Non-GAAP EPS FY25: $1.84
> Prior corpus coverage: None — first analysis of ALAB

---

## Summary

I haven't covered Astera Labs in the newsletter before, but applying my framework here produces a clear conclusion: this is a genuinely excellent AI infrastructure picks-and-shovels business trading at a price that leaves no room for error. Q4 FY25 delivered $270.6M in revenue (+92% YoY, +17.5% QoQ), the fourth consecutive beat averaging 9% above the midpoint guidance — a deliberate sandbagging pattern I find credible and repeatable. Full-year FY25 revenue reached $852.5M, up 115% year-over-year, with non-GAAP operating margin expanding to 39.2% for the year and 40.2% in Q4. FCF for the year was $281.8M at a 33.1% margin, and the balance sheet holds $1.19B in cash and marketable securities with zero debt. This is not a company executing poorly. But three post-earnings disclosures created a legitimate re-rating event: gross margin guided to ~74% for Q1 FY26 (with Amazon warrant contra-revenue adding ~200bp additional drag from Q2), OpEx guiding up $16–20M sequentially as R&D accelerates, and a CFO departure mid-cycle. The stock dropped 20%+. My assessment is that the selloff reflected rational repricing of the gross margin trajectory, not panic. At ~33x TTM EV/S on a decelerating growth rate, ALAB is priced for the Scorpio X ramp to deliver growth reacceleration in H2 FY26. That is a bet I find intellectually interesting but not yet compelling at this valuation. I would not initiate a position here. I would watch for the Scorpio X material ramp signal and a gross margin stabilisation, at which point a pullback to the 20–22x TTM range would be attractive.

---

## Headline KPIs: Q4 FY25

- **Revenue:** $270.6M | YoY +91.8% | QoQ +17.5%
- **Beat vs. guide:** +$20.1M vs. $250.5M midpoint | +8.0%
- **Non-GAAP gross margin:** 75.7% (d

*…truncated*